View Press Releases
BullFrog AI Strengthens Capabilities of its AI Platform Through Expansion of Licensing Agreement With Johns Hopkins Applied Physics Laboratory
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW)
("BullFrog AI" or the "Company"), a digital technology
company using machine learning to usher in a new era of precision
medicine, today announced the expansion of its worldwide license agreement
with the Johns Hopkins Applied Physics Laboratory (APL), in Laurel, Maryland,
for use of patented technology powering the Company’s bfLEAP™ platform, an
AI-driven platform for analyzing drug development data to potentially make
life-saving therapies and treatments available to patients more quickly.
“We are committed to firmly
establishing BullFrog AI as the undisputed leader in artificial
intelligence-driven drug development,” said Vin Singh, Founder and CEO of
BullFrog AI. "Our expanded license with APL is a testament to our relentless
pursuit of innovation, enabling us to harness the full potential of AI in
accelerating the development of life-saving therapies. This breakthrough
technology not only has the potential to disrupt the industry, but also
transform countless lives across the globe."
The patented technology from APL
powering bfLEAP™ includes analytical models that enable the analysis
and interpretation of large, complex, and diverse datasets that may be
incomplete and comprise both numerical and categorical data and provide
explainable results. The innovative technology, which enables the detection of
anomalies, patterns, and relationships, has been shown to perform better than
well-known algorithms in benchmarking tests.
The latest APL license improvements
enable bfLEAP™ capabilities to be much more robust, both from a
software perspective and mathematically. Additionally, the introduction of
multivariate diffuse indexing, a new algorithm for analysis of mixed
categorical/numerical data that supports both link inference and probabilistic
modeling, allows probabilistic models to work with mixed data without any
additional transformation.
Furthermore, the creation of a new
repository that now houses all of the graph algorithms has led to a more
organized structure with three equivalent-sized repositories containing around
80 runnable analytics each. This update brings numerous robustness and
usability improvements to the platform.
BullFrog AI is deploying bfLEAP™
for use at several critical stages of therapeutics development with the
intention of streamlining data analytics, decreasing the overall development
costs by decreasing failure rates for new therapeutics and impacting the lives
of countless patients that may otherwise not receive the therapies they need.
About BullFrog AI
BullFrog AI is a digital technology
company using machine learning to usher in a new era of precision medicine.
Through its collaborations with leading research institutions, including Johns
Hopkins University, BullFrog AI is at the forefront of AI-driven drug
development. Using its proprietary bfLEAP™ artificial intelligence
platform, BullFrog AI aims to enable the successful development of
pharmaceuticals and biologics by predicting which patients will respond to
therapies in development. BullFrog AI is deploying bfLEAP™ for use
at several critical stages of development with the intention of streamlining
data analytics in therapeutics development, decreasing the overall development
costs by decreasing failure rates for new therapeutics, and impacting the lives
of countless patients that may seek to receive the therapies they need.
For more information, visit
BullFrog AI at
Website: www.bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains
forward-looking statements. We base these forward-looking statements on our
expectations and projections about future events, which we derive from the
information currently available to us. Such forward-looking statements relate
to future events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings; and our
business prospects and opportunities. You can identify forward-looking
statements by those that are not historical in nature, particularly those that
use terminology such as "may," "should,"
"expects," "anticipates," "contemplates,"
"estimates," "believes," "plans,"
"projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various factors,
including: our ability to change the direction of the Company; our ability to
keep pace with new technology and changing market needs; and the competitive environment
of our business. These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking statements are
only predictions. The forward-looking events discussed in this press release
and other statements made from time to time by us or our representatives, may
not occur, and actual events and results may differ materially and are subject
to risks, uncertainties, and assumptions about us. We are not obligated to
publicly update or revise any forward-looking statement, whether as a result of
uncertainties and assumptions, the forward-looking events discussed in this
press release and other statements made from time to time by us or our
representatives might not occur.